Press Releases

IRVINE, Calif.--(BUSINESS WIRE)-- Nihon Kohden America, Inc. today announced that proceeds from the auction of its new EEG-1200A EEG Diagnostic and Monitoring system will be presented to the American Epilepsy Society (AES) in support of the Lennox and Lombroso Trust for Epilepsy Research and Training. The Cleveland Clinic Foundation will be recognized as the highest tender of $23,360.00. A check presentation ceremony will take place at 6:00 p.m. December 6th during the Lennox and Lombroso Trust for Research & Training Reception at the AES annual scientific meeting in Boston. AES president Steven C. Schachter, M.D., will be receiving the funds on behalf of the society.

Kathy Hart, Director of NKA's Neurology Business, says, "For over 50 years Nihon Kohden has continuously strived to work with healthcare thought leaders to introduce technological advancements to improve the diagnosis for people with epilepsy. Nihon Kohden is proud to provide 100% of the proceeds from the EEG-1200A auction to the Lennox and Lombroso Trust for Epilepsy Research and Training to augment support of the next generation's promising new scientists and research in Epilepsy."

"We appreciate the creative and generous way in which Nihon Kohden is supporting our efforts to expand the cadre of young scientists working to improve the lives of people with epilepsy," said Braxton B. Wannameker, M.D., who chairs the Lennox/Lombroso Trust committee. "Recent advances in neuroscience present unprecedented opportunities for discovery in epilepsy research. This support will further encourage and foster young investigators to come into the field."

About Nihon Kohden America

Nihon Kohden America was founded in 1979 as a wholly owned subsidiary of Nihon Kohden Corporation, Japan (founded in 1951). Nihon Kohden is a market leader in Patient Monitoring, Sleep Assessment, Neurology and Cardiology instrumentation. Our products are distributed to hospitals, physician's practices, mobile services, and outpatient and surgery centers throughout North America. For more than 50 years, healthcare providers worldwide have relied on the quality and reliability of Nihon Kohden's comprehensive and innovative line of neuro-diagnostic and -monitoring instrumentation to aid in the diagnosis, information and treatment of their patients.

Nihon Kohden's long legacy in EEG diagnostics and monitoring continues with the introduction of the EEG-1200A that combines EEG, Long Term Epilepsy, cEEG ICU Monitoring and Sleep Testing for the most flexible and comprehensive recording system available today. Our library of 32-192 channel amplifiers and AirEEG wireless technology offer superior signal quality and the highest recording specifications for discrete localization. The EEG-1200A system features a LAN connected, IP adjustable input converter for all amplifiers providing more configuration flexibility independent of the PC platform. Our MPEG4 digital video and audio software offers impressive time resolution playback of 1/30 second, full motion video as well as the ability to edit EEG and video during recording over the network. NeuroWorkbench(TM), the core integrator of Nihon Kohden's Neurology portfolio of IOM, EMG and EEG systems is the common interface for exam scheduling, protocol administration and data management improving workflow and access to clinical data and records.

More information about Nihon Kohden and our EEG-1200A technology can be found at www.nkusa.com.

About the Lennox and Lombroso Trust for Epilepsy Research & Training

AES is the world's leading organization for professional training in Epilepsy treatment and research. AES has an ongoing commitment to education and research, and has devoted a significant portion of its operating income to support them. Importantly, AES has emphasized basic and clinical research opportunities for fellows and junior faculty at critical starting points in their careers, and this has been accomplished via peer-reviewed grants in collaboration with the Epilepsy Foundation. Indeed, these seed funds have supported individuals who are now leaders in the field, and continue to attract the best academicians to our field.

The role of AES in assuring excellent research, training, and clinical care has become ever more important as support from the National Institutes of Health and industry dwindles. We can no longer rely solely on others to invest in the future of our next generation and must build from within to create a secure foundation for epilepsy Education and Research. To invigorate our Society's efforts for Research support, the AES leadership has chosen the newly created Lennox and Lombroso Trust for Research and Training as a key entity for growth. Current assets of the Trust approach $2.5 million, providing about $75,000 in yearly support for research and training. Our long term goal is to enable our endowment to provide an annual $300,000 grants program. Thus, the current level of endowment must increase fourfold to $10 million.

Times are changing for all of us, and our Society is adapting to these changes with a solid plan for the future of our members and our field. What will never change is the Society's commitment to epilepsy and to excellence.

Read more: http://www.aesnet.org/go/about-aes/donations#ixzz0V3nr2WWZ

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6111417&lang=en

    Source: Nihon Kohden America, Inc.

CARY, N.C., Dec. 6 /PRNewswire-FirstCall/ -- Sapiens International Corporation N.V. (Nasdaq and TASE: SPNS), a member of the Formula Group (Nasdaq: FORTY and TASE: FORT), today announced that it has paid the fourth and final installment of the principal amount of the convertible debentures (Series A) of the Company, in the amount of approximately $5.3 million. This completes Sapiens' payment of an aggregate amount of approximately $26.5 million of the principal amount of convertible debentures (Series A) of the Company.

The Company's announcement follows its recently released financial results for the third quarter of 2009, which showed the Company's twelfth consecutive quarter of operational profit and net income commencing from the third quarter of 2008.

Mr. Roni Al Dor, President & Chief Executive Officer of the Company said today:

"We view the final payment of the debentures as an important milestone in the lifecycle of the company. In the past few years, Sapiens has undergone a restructuring process in which we left no stone unturned in the company, and developed a business strategy which, I am happy to say, turned out to be a winning one. Payment of the debentures signifies, from our perspective, the character of Sapiens which does not compromise on business excellence while honoring all its obligations. Today, we are in a good financial position, and, after we have improved our bottom line, we are focussed on increasing our revenues by penetrating into new markets globally, as well as by exploring mergers and acquisitions with companies operating in synergetic fields. "

FOR ADDITIONAL INFORMATION:

Roni Giladi                               Roni Al-Dor
Chief Financial Officer                   Chief Executive Officer
Sapiens International                     Sapiens International
Tel: +972-8-938-2721                      Tel: +972-8-938-2721
E-mail: IR.Sapiens@sapiens.com            E-mail: IR.Sapiens@sapiens.com

About Sapiens International

Sapiens International Corporation N.V. (Nasdaq and TASE: SPNS), a member of Formula Group (Nasdaq: FORTY and TASE: FORT), which is a member of the Emblaze Group (LSE: BLZ.L) is a leading global provider of proven IT solutions that modernize business processes and enable insurance organizations to adapt quickly to change. Sapiens' innovative solutions are widely recognized for their ability to cost-effectively align IT with the business demands for speed, flexibility and efficiency. Sapiens operates through its subsidiaries in North America, the United Kingdom, EMEA and Asia Pacific, and has partnerships with market leaders such as IBM and EDS. Sapiens' clients include AXA, ING, Liverpool Victoria, Menora Mivtachim, Norwich Union, Occidental Fire & Casualty, OneBeacon, Principal Financial Group, Santam and Texas Farm Bureau among others. For more information, please visit http://www.sapiens.com.

Except for historical information contained herein, the matters set forth in this release are forward-looking statements that are dependent on certain risks and uncertainties, including such factors, among others, as market acceptance, market demand, pricing, changing regulatory environment, changing economic conditions, risks in new product and service development, the effect of the Company's accounting policies, specific system configurations and software needs of individual customers and other risk factors detailed in the Company's SEC filings.

SOURCE Sapiens International Corporation N.V.

OR YEHUDA, Israel, Dec. 6 /PRNewswire-FirstCall/ -- Magic Software Enterprises Ltd. (Nasdaq: MGIC), a provider of application platforms and business and process integration solutions, today announced the sale of its Israel-based company office building, for the sum of approximately $5.2 million in cash.

Further details of the transaction and its impact on Magic Software's financials will be provided in the company's 2009 fourth quarter and year-end earnings release.

About Magic Software

Magic Software Enterprises Ltd. (Nasdaq: MGIC) is a global provider of multiple-mode application platform solutions - including Full Client, Rich Internet Applications (RIA) or Software-as-a-Service (SaaS) modes - and business and process integration solutions. Magic Software has offices in 10 countries and a presence in over 50, as well as a global network of ISV's, system integrators, value-added distributors and resellers, and consulting and OEM partners. The company's award-winning code-free solutions give partners and customers the power to leverage existing IT resources, enhance business agility and focus on core business priorities. Magic Software's technological approach, product roadmap and corporate strategy are recognized by leading industry analysts. Magic Software has partnerships with global IT leaders including SAP AG, salesforce.com, IBM and Oracle. For more information about Magic Software and its products and services, visit www.magicsoftware.com, and for more about our industry related news, business issues and trends, read the Magic Software Blog.

Except for the historical information contained herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors including, but not limited to, risks in product and technology development, market acceptance of new products and continuing product conditions, both here and abroad, release and sales of new products by strategic resellers and customers, and other risk factors detailed in the Company's most recent annual report and other filings with the Securities and Exchange Commission.

Company contact:


Amit Birk
Vice President M&A and General Counsel
Magic Software Enterprises Ltd.
Tel. +972 (0)3 538 9292
Email: abirk@magicsoftware.com

SOURCE Magic Software Enterprises Ltd.

SEOUL, Korea, Dec. 6 /PRNewswire/ -- RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

Multiple Sclerosis is a disease in which the nerves of the central nervous system degenerate. MS can cause problems with muscle control and strength, vision, balance, feeling, and thinking. MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. When the myelin sheath is damaged, nerve impulses slow down or stop responding. From the many symptoms of MS, numbness or abnormal sensation in any area is predominant.

For the past 20 years, Park suffered from MS. For stem cell injection, she was admitted into Choyang Hospital of Regenerative Medicine in Yanji, China for three weeks. She received stem cells intravenously as well as intrathecally. The injections were given in five intervals -- a total of 1.2 billion cells.

Prior to stem cell treatment, Park suffered from Optic Neuritis -- a common symptom of MS. Some of the symptoms of Optic Neuritis include double vision, vision loss, and uncontrollable rapid eye movements. She was not able to recognize any writing due to her vision loss. After six months of receiving stem cell therapy, Park experienced phenomenal changes. Her vision improved drastically -- she was able to read. Furthermore, it also became possible for her to move her legs using her own muscular strength.

"My legs felt like hollow logs. They were so numb and stiff. However, after receiving stem cell treatment, I can actually feel my legs. I can also tell the difference in cold and warm temperatures. Stem cell therapy brought incredible changes to my physical condition," stated Kang Sook Park.

Park also added, "Receiving stem cell turned my life around. I feel like I am reborn. The fact that I am in this condition brings me new joy. I love the fact that I no longer need anyone's help to get from place to place. I would like to share my experience to others who may have this rare disease. I want to let others know that they can find hope through stem cell treatment, just the way I did."

Dr. Chang Won Kim reported Park's EMG findings before and after the stem cell treatment. "Patients who have an uncommon disease such as MS rarely show improvement or are completely cured. EMG results showed that Park's movement increased both in upper and lower limbs. Reduction in latency suggests that demyelination was also improved. It is extremely difficult for MS patients to use their own strength to even make small movements in the arms or legs. These changes in Park were possible through stem cell therapy."

President and CEO of RNL Bio, Dr. Jeong Chan Ra expressed, "The effective outcomes from stem cell treatment for rare diseases like Multiple Sclerosis can be used in the future. I will do my best to help improve the quality of life for people who are suffering from diseases like MS."

About RNL BIO CO., LTD.

RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has conducted two Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury. RNL is a publically traded company listed in the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

SOURCE RNL Bio Co., Ltd

WASHINGTON, Dec. 6 /PRNewswire-USNewswire/ -- Following is the daily "Profile America" feature from the U.S. Census Bureau:

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO)

SUNDAY, DECEMBER 6: CITRUS FRUIT

Profile America -- Sunday, December 6th. Along with the colorful decorations and music, the pleasure of the holidays is also enhanced by the seasonal flow of fresh citrus fruit. In the past, children were said to dream of sugar plums and receiving an orange at Christmas was a major gift. Now, online and mail order catalogs feature boxes of perfect fruit for last-minute gifts. We each consume nearly 22 pounds of fresh citrus fruit a year -- including 10 pounds of oranges, over two pounds of grapefruit and nine pounds of lemons, limes, tangerines, and tangelos. Florida is the nation's leading citrus producer -- other major producers are California and Texas. You can find these and more facts about sports in America from the U.S. Census Bureau online at www.census.gov.

Sources: Statistical Abstract of the United States 2009, t. 210, 824

Profile America is produced by the Public Information Office of the U.S. Census Bureau. These daily features are available as produced segments, ready to air, on a monthly CD or on the Internet at http://www.census.gov (look under the "Newsroom" button).

SOURCE U.S. Census Bureau